Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWJ1464 in Patients with Chronic Liver Disease
NCT06272630Phase 4Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of ursodeoxycholic acid in chronic liver disease (CLD), sponsored by Daewoong Pharmaceutical. Started Feb 2023; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on NCT06272630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06272630.